Janux Therapeutics price target raised to $200 from $100 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Janux Therapeutics (JANX) to $200 from $100 and keeps an Overweight rating on the shares. Janux Therapeutics reported data for JANX007 for metastatic castration-resistant prostate cancer patients that far exceeded the expectations the firm had captured in a survey a few week ago, and the data may continue to get better as the higher dose cohorts mature, the analyst tells investors in a research note. The firm says there were only minor things to nit-pick and that ‘007 demonstrated “unprecedented” rates of PSA50, PSA90, overall response rate, and a very well tolerated profile.